• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific says studies show real-world benefits of implantable CRM devices

Boston Scientific says studies show real-world benefits of implantable CRM devices

May 14, 2009 By MassDevice staff

Boston Scientific Corp. is touting a pair of studies it says indicate that implantable cardiac rhythm management devices perform better in the real world than they were predicted to in human clinical trials.

The studies, both of which were sponsored by the Natick-based devices leviathan, examined the real-world performance of its implantable cardioverter and cardiac resynchronization therapy defibrillators. The results were presented in Boston at a Heart Rhythm Society conference.

The first study analyzed data from the eight-year Madit II clinical study of implanted ICDs, comparing outcomes in heart attack patients with moderate impairment of the left ventricle with outcomes from drug therapy alone.

BSC said the results showed that a life is saved for every six patients implanted with the device, over the eight-year span of the trial. It also showed a 41 percent relative reduction in the risk of death at four years and a 37 percent reduction in the risk of death after eight years.

The trial Initial clinical trial results showed that ICDs reduced the relative risk of death by 31 percent after 20 months.

The second study, of data from BoSci’s Altitude Clinical Science program, analyzed data from the company’s Latitude patient management system. It’s tracked more than 130,000 patients since its 2006 inception, monitoring their implanted devices to detect clinical events between doctor’s visits and sending the data directly to physicians.

The Altitude study looked at data from nearly 86,000 of those patients, finding five-year survival rates for patients implanted with ICDs of up to 92 percent and of up to 78 percent for patients with CRTDs.

Company officials said those results exceed the survival rates from previous, randomized clinical trials, but did not quantify those prior results.

Filed Under: Business/Financial News Tagged With: Cardiac Rhythm Management

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy